FDA clears Siemens IV-MRI package
Siemens Medical Systems has received 510(k) marketing clearancefor an upgrade package for its Magnetom Open MRI scanner thatenables clinicians to perform MRI-guided procedures with the scanner.The FDA's move also allows the Iselin, NJ, vendor to promote
Siemens Medical Systems has received 510(k) marketing clearancefor an upgrade package for its Magnetom Open MRI scanner thatenables clinicians to perform MRI-guided procedures with the scanner.The FDA's move also allows the Iselin, NJ, vendor to promote theuse of Open for interventional imaging, which was not includedin Open's original 510(k) clearance document (SCAN 4/6/94).
Siemens' MR-Guided Procedures Package includes hardware suchas a bore light, ergonomic chair, foot pedal to initiate scans,multipurpose 35-cm coil, auto-display of images as they are acquired,and an optional in-room monitor. It also includes fast imagingsequences, according to Anne Deery Sheehan, Open product manager.
The package was designed to allow clinicians to conduct MR-guidedbiopsies and drainages on a range of anatomyfrom the head andneck to the spine, abdomen, and extremities. The package has beenunder evaluation at University Hospitals of Cleveland and at sevensites in Europe.
Siemens believes that the option is the first clinically availableMR-guided surgery package. Siemens will offer the package as anoption for installed Open scanners, with a list price of $155,000including in-room monitor. A new Open with the package will probablylist for around $1 million.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
